168 related articles for article (PubMed ID: 18191705)
1. Chemotherapy-induced toxic erythema under treatment with pegylated liposomal doxorubicin: No restriction to palms and soles.
Ziemer M; Goetze S; Kaatz M; Elsner P
J Am Acad Dermatol; 2008 Feb; 58(2 Suppl):S44-6. PubMed ID: 18191705
[No Abstract] [Full Text] [Related]
2. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia.
Lopez AM; Wallace L; Dorr RT; Koff M; Hersh EM; Alberts DS
Cancer Chemother Pharmacol; 1999; 44(4):303-6. PubMed ID: 10447577
[TBL] [Abstract][Full Text] [Related]
3. Distal phalange necrosis: a severe manifestation of palmar plantar erythrodysesthesia.
Palaia I; Angioli R; Bellati F; Basile S; Rabitti C; Panici PB
Am J Obstet Gynecol; 2006 Oct; 195(4):e1-2. PubMed ID: 16875651
[TBL] [Abstract][Full Text] [Related]
4. Severe palmoplantar erythrodysesthesia and intertrigolike eruption induced by polyethylene glycol-coated liposomal doxorubicin.
Campanelli A; Kerl K; Lübbe J
J Eur Acad Dermatol Venereol; 2006 Sep; 20(8):1022-4. PubMed ID: 16922969
[No Abstract] [Full Text] [Related]
5. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
[TBL] [Abstract][Full Text] [Related]
6. Hand-foot syndrome.
Pike K
Oncol Nurs Forum; 2001; 28(10):1519-20. PubMed ID: 11759299
[No Abstract] [Full Text] [Related]
7. Palmar-plantar erythrodysesthesia.
Wilkes GM; Doyle D
Clin J Oncol Nurs; 2005 Feb; 9(1):103-6. PubMed ID: 15751504
[No Abstract] [Full Text] [Related]
8. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
[TBL] [Abstract][Full Text] [Related]
9. ["Hand-foot" syndrome--after liposomal pegylated doxorubicin in patients with the ovarian cancer recurrence (own experiences)].
Mrochen-Domin I; Nowara E; Kaleta B
Ginekol Pol; 2008 May; 79(5):332-7. PubMed ID: 18624107
[TBL] [Abstract][Full Text] [Related]
10. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.
Webster-Gandy JD; How C; Harrold K
Eur J Oncol Nurs; 2007 Jul; 11(3):238-46. PubMed ID: 17350337
[TBL] [Abstract][Full Text] [Related]
11. The hand-foot syndrome--a frequent secondary manifestation in antineoplastic chemotherapy.
Janusch M; Fischer M; Marsch WCh; Holzhausen HJ; Kegel T; Helmbold P
Eur J Dermatol; 2006; 16(5):494-9. PubMed ID: 17101468
[TBL] [Abstract][Full Text] [Related]
12. Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience.
Rossi D; Catalano G
Oncology; 2007; 73(3-4):277-8. PubMed ID: 18424894
[No Abstract] [Full Text] [Related]
13. [Liposomal doxorubicin and palmoplantar erythrodysesthesia].
Tomb R; Stephan F; Halaby G
Ann Dermatol Venereol; 2003 Nov; 130(11):1057-8. PubMed ID: 14724543
[No Abstract] [Full Text] [Related]
14. Chemotherapy-induced acral erythema in a pediatric patient with acute monoblastic leukemia.
Demircioğlu F; Oren H; Yilmaz S; Arslansoyu S; Eren S; Irken G
Pediatr Hematol Oncol; 2008; 25(3):211-5. PubMed ID: 18432504
[TBL] [Abstract][Full Text] [Related]
15. Histologic patterns of polyethylene glycol-liposomal doxorubicin-related cutaneous eruptions.
Cady FM; Kneuper-Hall R; Metcalf JS
Am J Dermatopathol; 2006 Apr; 28(2):168-72. PubMed ID: 16625083
[TBL] [Abstract][Full Text] [Related]
16. Severe palmar-plantar erythema in a patient with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy.
Damasiewicz MJ; Chionh FJ; Hayes T
Intern Med J; 2007 Jul; 37(7):505-6. PubMed ID: 17547732
[No Abstract] [Full Text] [Related]
17. Chemotherapy-induced palmer planter erythrodysesthesia.
Bhasin S; Sunita ; Gupta DK; Kataria SP; Saluja S; Sharma M
J Assoc Physicians India; 2005 Feb; 53():155-6. PubMed ID: 15847041
[TBL] [Abstract][Full Text] [Related]
18. Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.
Katsumata N; Fujiwara Y; Kamura T; Nakanishi T; Hatae M; Aoki D; Tanaka K; Tsuda H; Kamiura S; Takehara K; Sugiyama T; Kigawa J; Fujiwara K; Ochiai K; Ishida R; Inagaki M; Noda K
Jpn J Clin Oncol; 2008 Nov; 38(11):777-85. PubMed ID: 18927230
[TBL] [Abstract][Full Text] [Related]
19. [Hand-foot syndrome (palmar-plantar erythrodysesthesia].
Salzberg M; Herrmann R
Schweiz Med Wochenschr; 2000 Oct; 130(40):1413-6. PubMed ID: 11059033
[TBL] [Abstract][Full Text] [Related]
20. Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn.
Markman M; Kulp B; Peterson G
Gynecol Oncol; 2004 Aug; 94(2):578-80. PubMed ID: 15297208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]